CompletedNot Applicable

Tumor DNA and MRI/CT Scan Findings in Patients With Grade III or Grade IV Malignant Glioma

42 participantsStarted 2005-04

Plain-language summary

RATIONALE: Studying levels of tumor DNA in the samples of blood from patients with cancer may help doctors find out whether the cancer has grown and how much. PURPOSE: This laboratory study is comparing levels of tumor DNA with MRI and CT scan findings to measure cancer growth in patients with grade III or grade IV malignant glioma.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Histologically confirmed malignant brain tumor * One of the following grade III or IV supratentorial gliomas: * Anaplastic astrocytoma * Anaplastic oligodendroglioma * Glioblastoma multiforme * Newly diagnosed or recurrent disease * Planning to undergo anticancer therapy on a New Approaches to Brain Tumor Therapy (NABTT) Consortium clinical trial PATIENT CHARACTERISTICS: * Karnofsky performance status 60-100% PRIOR CONCURRENT THERAPY: * See Disease Characteristics

What they're measuring

Total plasma glioma-specific DNA concentration

Timeframe: every 2 months until death

Tumor size

Timeframe: every 2 months until death

Trial details

NCT IDNCT00897611

SponsorSidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2009-08

View on ClinicalTrials.gov More High Grade Glioma trials